Molbio Diagnostics Limited
MOLBIO · 544866 · Healthcare · Medical Equipment & Supplies
- Market cap
- Rs 14,688 Cr
- P/E
- 88.19x
- P/B
- No data: the source has not published this figure.
- 52W high / low
- No data: the source has not published this figure.
No earnings evidence was available to confirm the P/E basis; treat as unverified.
About Molbio Diagnostics
Molbio Diagnostics Limited is listed on the NSE under the symbol MOLBIO and on the BSE under scrip code 544866. It is classified in the Healthcare sector, industry: Medical Equipment & Supplies. It is a constituent of BSE IPO. The company listed on 17 Aug 2026 and has a face value of Rs 1.
The latest available end-of-day price is Rs 1,302.6 (−0.77% on the day), for a market capitalisation of Rs 14,688 Cr. Trailing P/E is 88.19x.
Against the 5-company comparison set from the official BSE basic industry Medical Equipment & Supplies, its market capitalisation is 3.0 times the peer median of Rs 4,850 Cr, and its P/E of 88.19x compares with a peer median of 59.23x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Molbio Diagnostics Limited reported revenue of Rs 1,446 Cr and net profit of Rs 164 Cr, with a net margin of 11.35% and earnings per share of Rs 14.77 (consolidated statements).
Year-on-year change: revenue +41.68%; net profit +18.45%; EPS +14.76%.
At the same date the balance sheet shows operating cash flow of Rs 50.4 Cr.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Molbio Diagnostics Limited's ownership is split: promoters 41.29%; foreign institutional investors (FIIs) 1.59%; domestic institutional investors (DIIs) 19.08%; retail and other shareholders 38.04%.
Compared with the filing for 30 Jun 2026: promoter holding 0.00 percentage points; FII holding +0.08 percentage points; DII holding +2.71 percentage points.
The same filing lists reported promoter pledge of 0.00% and 50,395 shareholders on record.
Recent filings and corporate actions
24 BSE corporate announcements were filed by Molbio Diagnostics Limited in the past twelve months; the most frequent category is "Company Update" (11). The most recent is "Clarification on Spurt in Volume of shares of the Company." (Company Update), filed on 19 Oct 2026.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Medical Equipment & Supplies. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Poly Medicure Limited | Rs 1,461.9 | Rs 14,818 Cr | Rs 2,109 Cr | Rs 313 Cr | 47.02x | 10.73% |
| Molbio Diagnostics LimitedThis company | Rs 1,302.6 | Rs 14,688 Cr | — | — | 88.19x | — |
| Sahajanand Medical Technologies Limited | Rs 476.55 | Rs 4,850 Cr | — | — | 71.45x | — |
| Fischer Medical Ventures Limited | Rs 25.93 | Rs 1,697 Cr | Rs 373 Cr | Rs 29.8 Cr | 10.80x | 8.25% |
| Tarsons Products Limited | Rs 303.95 | Rs 1,617 Cr | Rs 468 Cr | Rs 11.1 Cr | — | 1.75% |
| Median | Rs 476.55 | Rs 4,850 Cr | Rs 468 Cr | Rs 29.8 Cr | 59.23x | 8.25% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Molbio Diagnostics
Same official industry (Medical Equipment & Supplies)
Other Healthcare companies of a similar market capitalisation
- Pfizer LimitedPFIZER · Market cap Rs 17,201 Cr
- Eris Lifesciences LimitedERIS · Market cap Rs 16,139 Cr
- Syngene International LimitedSYNGENE · Market cap Rs 16,091 Cr
- Vijaya Diagnostic Centre LimitedVIJAYA · Market cap Rs 15,066 Cr
- Jubilant Pharmova LimitedJUBLPHARMA · Market cap Rs 14,947 Cr
- Indegene LimitedINDGN · Market cap Rs 14,272 Cr
- Natco Pharma LimitedNATCOPHARM · Market cap Rs 14,097 Cr
- Concord Biotech LimitedCONCORDBIO · Market cap Rs 12,874 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.